Q2 FY2026 EarningsQ2 FY26 missed consensus on revenue and profitability: revenue $5.18M vs. $5.66M expected, and GAAP EPS -$0.85 vs. -$1.22 expected (reflecting a narrower loss driven by cost efficiencies). Services revenue declined significantly YoY, primarily due to non-recurring pharmaceutical partner revenue, while consumer hardware grew. Management secured a $23.5M registered direct offering subsequent to quarter-end to address liquidity concerns following a cash balance drop to $6.6M.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: DarioHealth(DRIO) the Revenue is 5.177 M (-3.58%), Miss estimate;the EBIT is -6.479 M (+29.58%), Beat estimate;the EPS is -0.85 (+76.39%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueMiss expectations
0.01B3.58%
0.01B5.35%
-0.00B8.93%
EBITExceed expectations
-0.01B29.58%
-0.01B23.37%
+0.00B6.21%
EPSExceed expectations
-0.8576.39%
-1.21566.25%
+0.365010.14%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf